Tags

Type your tag names separated by a space and hit enter

Kala-azar associated with coombs-positive autoimmune hemolytic anemia in the patients coming from the endemic area of this disease and successful treatment of these patients with liposomal amphotericin B.
Pediatr Hematol Oncol. 2005 Jul-Aug; 22(5):349-55.PH

Abstract

Kala-azar is an intracellular parasitic infection that infects and multiplies in the macrophages of the liver, the spleen, and the bone marrow. It is characterized by intermittent fever, hepatosplenomegaly, pancytopenia, and hypergammaglobulinemia. Although anemia is a usual finding, Coombs-positive autoimmune hemolytic anemia (AIHA) has rarely been reported with this disease. Pentavalent antimonial compounds remain the mainstay of treatment worldwide. Liposomal amphotericin B (L-AmB) is currently preferred in the treatment of kala-azar because of the resistance to pentavalent antimonals. The authors diagnosed kala-azar associated with Coombs-positive AIHA in 3 patients and treated them with L-AmB (1-5 mg/kg/day) for 30-36 days. Now, all of these patients are healthy following up at the outpatient base for 18-34 months. Kala-azar must be considered in patients with Coombs-positive AIHA and living in and coming from the endemic region for this disease, and it can be successfully treated with L-AmB.

Authors+Show Affiliations

Erduran E
Karadeniz Technical University, School of Medicine, Department of Pediatrics, Trabzon, Turkey. erduran@ktu.edu.tr
Bahadir A
No affiliation info available
Gedik Y
No affiliation info available

MeSH

Amphotericin BAnemia, HemolyticChild, PreschoolCoombs TestEndemic DiseasesFemaleHumansInfantLeishmaniasis, VisceralLiposomesTreatment OutcomeTurkey

Pub Type(s)

Case Reports
Journal Article

Language

eng

PubMed ID

16020124

Citation

Erduran, Erol, et al. "Kala-azar Associated With Coombs-positive Autoimmune Hemolytic Anemia in the Patients Coming From the Endemic Area of This Disease and Successful Treatment of These Patients With Liposomal Amphotericin B." Pediatric Hematology and Oncology, vol. 22, no. 5, 2005, pp. 349-55.
Erduran E, Bahadir A, Gedik Y. Kala-azar associated with coombs-positive autoimmune hemolytic anemia in the patients coming from the endemic area of this disease and successful treatment of these patients with liposomal amphotericin B. Pediatr Hematol Oncol. 2005;22(5):349-55.
Erduran, E., Bahadir, A., & Gedik, Y. (2005). Kala-azar associated with coombs-positive autoimmune hemolytic anemia in the patients coming from the endemic area of this disease and successful treatment of these patients with liposomal amphotericin B. Pediatric Hematology and Oncology, 22(5), 349-55.
Erduran E, Bahadir A, Gedik Y. Kala-azar Associated With Coombs-positive Autoimmune Hemolytic Anemia in the Patients Coming From the Endemic Area of This Disease and Successful Treatment of These Patients With Liposomal Amphotericin B. Pediatr Hematol Oncol. 2005 Jul-Aug;22(5):349-55. PubMed PMID: 16020124.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Kala-azar associated with coombs-positive autoimmune hemolytic anemia in the patients coming from the endemic area of this disease and successful treatment of these patients with liposomal amphotericin B. AU - Erduran,Erol, AU - Bahadir,Aysenur, AU - Gedik,Yusuf, PY - 2005/7/16/pubmed PY - 2005/11/8/medline PY - 2005/7/16/entrez SP - 349 EP - 55 JF - Pediatric hematology and oncology JO - Pediatr Hematol Oncol VL - 22 IS - 5 N2 - Kala-azar is an intracellular parasitic infection that infects and multiplies in the macrophages of the liver, the spleen, and the bone marrow. It is characterized by intermittent fever, hepatosplenomegaly, pancytopenia, and hypergammaglobulinemia. Although anemia is a usual finding, Coombs-positive autoimmune hemolytic anemia (AIHA) has rarely been reported with this disease. Pentavalent antimonial compounds remain the mainstay of treatment worldwide. Liposomal amphotericin B (L-AmB) is currently preferred in the treatment of kala-azar because of the resistance to pentavalent antimonals. The authors diagnosed kala-azar associated with Coombs-positive AIHA in 3 patients and treated them with L-AmB (1-5 mg/kg/day) for 30-36 days. Now, all of these patients are healthy following up at the outpatient base for 18-34 months. Kala-azar must be considered in patients with Coombs-positive AIHA and living in and coming from the endemic region for this disease, and it can be successfully treated with L-AmB. SN - 0888-0018 UR - https://www.unboundmedicine.com/medline/citation/16020124/Kala_azar_associated_with_coombs_positive_autoimmune_hemolytic_anemia_in_the_patients_coming_from_the_endemic_area_of_this_disease_and_successful_treatment_of_these_patients_with_liposomal_amphotericin_B_ DB - PRIME DP - Unbound Medicine ER -